|
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interferon-α2b is FDA approved drug for the treatment of chronic HCV and HBV, melanoma, AIDS-related KS, carcinomas, hairy cell leukemia and chronic myelogenous leukemia.
|
31612813 |
2020 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interferon-α2b is FDA approved drug for the treatment of chronic HCV and HBV, melanoma, AIDS-related KS, carcinomas, hairy cell leukemia and chronic myelogenous leukemia.
|
31612813 |
2020 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Boosting of Hepatitis B Virus-Specific T Cell Responses After Pegylated-Interferon-α-2a Therapy for Hepatitis B e Antigen-Positive Pediatric Patients.
|
31329012 |
2019 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the 1990s, interferons alpha-2 were used in the treatment of HCV and in the next decade HCV therapy was based on pegylated interferon alpha-2 in combination with ribavirin.
|
30685524 |
2019 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, the use of latent IFNα2b can be considered again as an option for treatment of HCV infection in combination with direct acting antivirals rather than alone with improved safety profile.
|
31350425 |
2019 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sustained virological response (SVR) in hepatitis C virus (HCV) patients treated with pegylated interferon α-2a and ribavirin is associated with reduced insulin resistance (IR), measured as a reduction of homeostasis model assessment (HOMA) scores after 24 weeks of therapy, and reduced fasting serum insulin and serum glucose levels.
|
31602234 |
2019 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pegylated interferon α-2a/- 2b plus ribavirin was administered for either 24 or 48 weeks depending on the HCV genotype.
|
29529840 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The findings of this review include the following: The use of interferon-α2b will be restricted for patients with ulcerated primary melanoma in countries with no access to new drugs in adjuvant therapy.
|
31236710 |
2019 |
|
Hepatitis B, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.
|
31487005 |
2019 |
|
Hepatitis C, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Comparison of Compliance and Efficacy of Pegylated Interferon α-2a and α-2b in Adults with Chronic Hepatitis C.
|
30855203 |
2019 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
The enhanced function of pDC and IFN-α2 might involve triggering the immune response from IT to hepatitis active phase in HBV infection.
|
29271379 |
2018 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aims to investigate the antiviral effect of polyethylene glycol (PEG)-interferon α-2a and PEG-interferon α-2b treatment on hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) at the 48th week of treatment and the 24th and 48th week after withdrawal, in order to provide guidance on the antiviral treatment of HBeAg-positive CHB patients.
|
29055925 |
2018 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IFN-α2 elevation was associated with ALT level in patients with chronic HBV infection.
|
30058578 |
2018 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Higher efficacy of pegylated interferon-α2b add-on therapy in hepatitis B envelope antigen-positive chronic hepatitis B patients on tenofovir monotherapy.
|
29314573 |
2018 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
The objective of the present analysis is to describe the change in neutrophil count resulting from peglated interferon alpha 2-a (PEG-IFN α-2a) therapy in HCV-infected patients.
|
29872876 |
2018 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pegylated interferon alpha 2a (PEG-IFN alpha 2a) alone, in combination with ribavirin and with or without direct acting antivirals (DAAs) is modestly effective in the treatment of chronic HCV infection.
|
29271660 |
2018 |
|
Hepatitis B, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aims to investigate the antiviral effect of polyethylene glycol (PEG)-interferon α-2a and PEG-interferon α-2b treatment on hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) at the 48th week of treatment and the 24th and 48th week after withdrawal, in order to provide guidance on the antiviral treatment of HBeAg-positive CHB patients.
|
29055925 |
2018 |
|
Hepatitis C, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection.
|
29872876 |
2018 |
|
Hepatitis C, Chronic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Ribavirin, a nucleic acid analog, has been employed as an antiviral agent against RNA and DNA viruses and has become the standard agent used for chronic hepatitis C in combination with interferon-α2a.
|
29251333 |
2018 |
|
Hepatitis C, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
The gene targets were selected in patients with the IFN-mediated disease chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) and an adult patient with chronic hepatitis C who received the first dose of pegylated interferon alpha-2a.
|
29638206 |
2018 |
|
Hepatitis B
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IFNA2 p.Ala120Thr impairs the inhibitory activity of Interferon-α2 against the hepatitis B virus through altering its binding to the receptor.
|
28958921 |
2017 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment.
|
28229987 |
2017 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The reduction in HBV DNA levels by TRK-560 treatment was significantly higher than that by PEG-IFN-α2a treatment both <i>in vitro</i> and <i>in vivo</i> (<i>P</i> = 0.004 and <i>P</i> = 0.046, respectively), and intracellular HBV covalently closed circular DNA (cccDNA) reduction by TRK-560 treatment was also significantly higher than that by PEG-IFN-α2a treatment <i>in vivo</i> (<i>P</i> = 0.0495). cDNA microarrays and ELISA for CXCL10 production revealed significant differences between TRK-560 and PEG-IFN-α2a in the induction potency of interferon-stimulated genes.
|
28373196 |
2017 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
ADJ higher doses of RBV based on its early pharmacokinetics-based RBV do not improve SVR rates in HCV GT4 treated in combination with peg-IFN alpha-2-a versus STD therapy.
|
29135370 |
2017 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interferon α2 is an antiviral/antiproliferative protein that is currently used to treat hepatitis C infections and several forms of cancer.
|
28731677 |
2017 |